Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration
Open Access
- 10 November 2020
- journal article
- letter
- Published by Elsevier BV in Allergology International
- Vol. 70 (2), 269-270
- https://doi.org/10.1016/j.alit.2020.09.012
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitisDermatologic Therapy, 2020
- Treatment of urticarial vasculitis: A systematic reviewJournal of Allergy and Clinical Immunology, 2019
- Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?Thrombosis and Haemostasis, 2017
- Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndromeJournal of the European Academy of Dermatology and Venereology, 2017
- Effectiveness of omalizumab in a case of urticarial vasculitisClinical and Experimental Dermatology, 2017
- Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitisClinical and Experimental Dermatology, 2014
- TWO CASES OF HÆMORRHAGIC URTICARIA.The Lancet, 1890